PAVmed Inc.

NasdaqCM:PAVM Stock Report

Market Cap: US$7.0m

PAVmed Valuation

Is PAVM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PAVM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$15.47
Fair Value
96.0% undervalued intrinsic discount
3
Number of Analysts

Below Fair Value: PAVM ($0.61) is trading below our estimate of fair value ($15.47)

Significantly Below Fair Value: PAVM is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PAVM?

Key metric: As PAVM is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for PAVM. This is calculated by dividing PAVM's market cap by their current earnings.
What is PAVM's PE Ratio?
PE Ratio0.5x
EarningsUS$14.72m
Market CapUS$7.02m

Price to Earnings Ratio vs Peers

How does PAVM's PE Ratio compare to its peers?

The above table shows the PE ratio for PAVM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average16.3x
DXR Daxor
22.4xn/aUS$39.0m
FONR FONAR
11.2xn/aUS$103.7m
SRTS Sensus Healthcare
15.1x-2.3%US$148.3m
PDEX Pro-Dex
16.6x5.8%US$105.9m
PAVM PAVmed
0.5x-90.0%US$7.0m

Price-To-Earnings vs Peers: PAVM is good value based on its Price-To-Earnings Ratio (0.5x) compared to the peer average (16.3x).

Price to Earnings Ratio vs Industry

How does PAVM's PE Ratio compare vs other companies in the US Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.35.3x12.5%
PAVM PAVmed
 0.5x-90.0%US$7.02m
MHUA Meihua International Medical Technologies
1.1xn/aUS$10.40m
UTRS Minerva Surgical
n/an/aUS$8.00
No more companies available in this PE range
PAVM 0.5xIndustry Avg. 35.3xNo. of Companies8PE020406080100+
3 CompaniesEstimated GrowthMarket Cap
Industry Avg.35.3x12.5%
PAVM PAVmed
 0.5x-90.0%US$7.02m
No more companies

Price-To-Earnings vs Industry: PAVM is good value based on its Price-To-Earnings Ratio (0.5x) compared to the US Medical Equipment industry average (35.5x).

Price to Earnings Ratio vs Fair Ratio

What is PAVM's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PAVM PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio0.5x
Fair PE Ratio1.8x

Price-To-Earnings vs Fair Ratio: PAVM is good value based on its Price-To-Earnings Ratio (0.5x) compared to the estimated Fair Price-To-Earnings Ratio (1.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PAVM forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.61
US$9.00
+1,366.0%
78.6%US$19.00US$4.00n/a3
Jan ’26US$0.63
US$9.00
+1,334.3%
78.6%US$19.00US$4.00n/a3
Dec ’25US$0.97
US$9.67
+896.6%
82.9%US$21.00US$4.00n/a3
Nov ’25US$1.03
US$9.67
+841.3%
82.9%US$21.00US$4.00n/a3
Oct ’25US$1.33
US$9.67
+626.8%
82.9%US$21.00US$4.00n/a3
Sep ’25US$0.91
US$10.00
+998.9%
84.9%US$22.00US$4.00n/a3
Aug ’25US$0.80
US$11.67
+1,355.1%
65.0%US$22.00US$4.00n/a3
Jul ’25US$0.76
US$11.67
+1,427.1%
65.0%US$22.00US$4.00n/a3
Jun ’25US$1.45
US$13.00
+796.6%
72.4%US$26.00US$4.00n/a3
May ’25US$2.31
US$15.38
+565.6%
59.4%US$26.00US$4.00n/a4
Apr ’25US$2.04
US$16.38
+702.7%
63.4%US$30.00US$4.00n/a4
Mar ’25US$2.74
US$20.63
+652.7%
30.2%US$30.00US$15.00n/a4
Feb ’25US$2.23
US$20.63
+824.9%
30.2%US$30.00US$15.00US$0.664
Jan ’25US$4.12
US$20.63
+400.6%
30.2%US$30.00US$15.00US$0.634
Dec ’24US$4.50
US$39.37
+775.0%
96.5%US$105.00US$15.00US$0.974
Nov ’24US$3.81
US$40.87
+973.7%
90.8%US$105.00US$15.00US$1.034
Oct ’24US$4.42
US$40.87
+825.0%
90.8%US$105.00US$15.00US$1.334
Sep ’24US$5.59
US$42.75
+664.5%
94.4%US$112.50US$15.00US$0.914
Aug ’24US$5.68
US$44.62
+685.0%
87.8%US$112.50US$21.00US$0.804
Jul ’24US$6.12
US$44.62
+629.5%
87.8%US$112.50US$21.00US$0.764
Jun ’24US$6.37
US$44.62
+600.2%
87.8%US$112.50US$21.00US$1.454
May ’24US$6.82
US$45.94
+574.0%
88.4%US$116.25US$22.50US$2.314
Apr ’24US$5.60
US$47.81
+753.4%
91.7%US$123.75US$22.50US$2.044
Mar ’24US$6.76
US$53.44
+691.0%
77.9%US$123.75US$22.50US$2.744
Feb ’24US$7.68
US$53.44
+595.8%
77.9%US$123.75US$22.50US$2.234
Analyst Price Target
Consensus Narrative from 3 Analysts
US$9.00
Fair Value
93.2% undervalued intrinsic discount
3
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/06 04:12
End of Day Share Price 2025/02/06 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PAVmed Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward WooAscendiant Capital Markets LLC
Raymond MyersBenchmark Company
Charles DuncanCantor Fitzgerald & Co.